Stine A Danielsen
Overview
Explore the profile of Stine A Danielsen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1200
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Burocziova M, Burdova K, Martinikova A, Kasparek P, Kleiblova P, Danielsen S, et al.
Cell Death Dis
. 2019 Oct;
10(11):818.
PMID: 31659152
Protein phosphatase magnesium-dependent 1 delta (PPM1D) terminates cell response to genotoxic stress by negatively regulating the tumor suppressor p53 and other targets at chromatin. Mutations in the exon 6 of...
2.
Smeby J, Sveen A, Bergsland C, Eilertsen I, Danielsen S, Eide P, et al.
ESMO Open
. 2019 Jul;
4(3):e000523.
PMID: 31321083
Background: Accumulating evidence suggests immunomodulatory and context-dependent effects of mutations in cancer. We performed an exploratory analysis of the transcriptional, immunobiological and prognostic associations of mutations within the gene expression-based...
3.
Berg K, Sveen A, Holand M, Alagaratnam S, Berg M, Danielsen S, et al.
Oncogene
. 2019 Jul;
38(33):6109-6122.
PMID: 31308487
About 80% of colorectal cancers (CRCs) have chromosomal instability, which is an integral part of aggressive malignancy development, but the importance of specific copy number aberrations (CNAs) in modulating gene...
4.
Smeby J, Sveen A, Eilertsen I, Danielsen S, Hoff A, Eide P, et al.
Oncogenesis
. 2019 May;
8(6):35.
PMID: 31092812
TP53 mutations are common in colorectal cancer (CRC). Most TP53 sequencing studies have been restricted to coding regions, but recent studies have revealed that splice mutations can generate transcript variants...
5.
Sveen A, Bruun J, Eide P, Eilertsen I, Ramirez L, Murumagi A, et al.
Clin Cancer Res
. 2017 Dec;
24(4):794-806.
PMID: 29242316
Response to standard oncologic treatment is limited in colorectal cancer. The gene expression-based consensus molecular subtypes (CMS) provide a new paradigm for stratified treatment and drug repurposing; however, drug discovery...
6.
Berg K, Eide P, Eilertsen I, Johannessen B, Bruun J, Danielsen S, et al.
Mol Cancer
. 2017 Jul;
16(1):116.
PMID: 28683746
Background: Colorectal cancer (CRC) cell lines are widely used pre-clinical model systems. Comprehensive insights into their molecular characteristics may improve model selection for biomedical studies. Methods: We have performed DNA,...
7.
Kolberg M, Bruun J, Murumagi A, Mpindi J, Bergsland C, Holand M, et al.
Mol Oncol
. 2017 May;
11(9):1156-1171.
PMID: 28556483
Patients with malignant peripheral nerve sheath tumor (MPNST), a rare soft tissue cancer associated with loss of the tumor suppressor neurofibromin (NF1), have poor prognosis and typically respond poorly to...
8.
Vedeld H, Merok M, Jeanmougin M, Danielsen S, Honne H, Presthus G, et al.
Int J Cancer
. 2017 May;
141(5):967-976.
PMID: 28542846
The prognostic value of CpG island methylator phenotype (CIMP) in colorectal cancer remains unsettled. We aimed to assess the prognostic value of this phenotype analyzing a total of 1126 tumor...
9.
Sveen A, Johannessen B, Tengs T, Danielsen S, Eilertsen I, Lind G, et al.
Genome Med
. 2017 May;
9(1):46.
PMID: 28539123
Background: Approximately 15% of primary colorectal cancers have DNA mismatch repair deficiency, causing a complex genome with thousands of small mutations-the microsatellite instability (MSI) phenotype. We investigated molecular heterogeneity and...
10.
Domingo E, Freeman-Mills L, Rayner E, Glaire M, Briggs S, Vermeulen L, et al.
Lancet Gastroenterol Hepatol
. 2017 Apr;
1(3):207-216.
PMID: 28404093
Background: Precision cancer medicine depends on defining distinct tumour subgroups using biomarkers that may occur at very modest frequencies. One such subgroup comprises patients with exceptionally mutated (ultramutated) cancers caused...